{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T18:17:41Z","timestamp":1788027461840,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,29]]},"DOI":"10.7759\/cureus.115406","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:31:41Z","timestamp":1788024701000},"source":"Crossref","is-referenced-by-count":0,"title":["Suzetrigine: A Selective Inhibitor of the NaV1.8 Sodium Channel"],"prefix":"10.7759","author":[{"given":"Daniel","family":"Bach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramveer","family":"Brar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Pemminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000000352","article-title":"ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative pain","volume":"56","author":"Hegmann KT","year":"2014","unstructured":"Hegmann KT, Weiss MS, Bowden K, et al.. ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative pain. J Occup Environ Med. 2014, 56:e143-59. 10.1097\/JOM.0000000000000352","journal-title":"J Occup Environ Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30430-1","article-title":"Perioperative opioid analgesia\u2014when is enough too much? A review of opioid-induced tolerance and hyperalgesia","volume":"393","author":"Colvin LA","year":"2019","unstructured":"Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia\u2014when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet. 2019, 393:1558-68. 10.1016\/S0140-6736(19)30430-1","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-023-01137-y","article-title":"Rational multimodal analgesia for perioperative pain management","volume":"27","author":"Joshi GP","year":"2023","unstructured":"Joshi GP. Rational multimodal analgesia for perioperative pain management. Curr Pain Headache Rep. 2023, 27:227-37. 10.1007\/s11916-023-01137-y","journal-title":"Curr Pain Headache Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.0898","article-title":"Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review","volume":"152","author":"Wick EC","year":"2017","unstructured":"Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review. JAMA Surg. 2017, 152:691-7. 10.1001\/jamasurg.2017.0898","journal-title":"JAMA Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16844","article-title":"Effect of a postoperative multimodal opioid-sparing protocol vs standard opioid prescribing on postoperative opioid consumption after knee or shoulder arthroscopy: a randomized clinical trial","volume":"328","author":"Gazendam A","year":"2022","unstructured":"Gazendam A, Ekhtiari S, Horner NS, et al.. Effect of a postoperative multimodal opioid-sparing protocol vs standard opioid prescribing on postoperative opioid consumption after knee or shoulder arthroscopy: a randomized clinical trial. J Am Med Assoc. 2022, 328:1326-35. 10.1001\/jama.2022.16844","journal-title":"J Am Med Assoc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.2012.01177.x","article-title":"Challenges in the management of acute postsurgical pain","volume":"32","author":"Oderda G","year":"2012","unstructured":"Oderda G. Challenges in the management of acute postsurgical pain. Pharmacotherapy. 2012, 32:6S-11S. 10.1002\/j.1875-9114.2012.01177.x","journal-title":"Pharmacotherapy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00582-7","article-title":"Opioid versus opioid-free analgesia after surgical discharge: a systematic review and meta-analysis of randomised trials","volume":"399","author":"Fiore JF","year":"2022","unstructured":"Fiore JF, El-Kefraoui C, Chay MA, et al.. Opioid versus opioid-free analgesia after surgical discharge: a systematic review and meta-analysis of randomised trials. Lancet. 2022,  399:2280-93. 10.1016\/S0140-6736(22)00582-7","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpa.2017.07.002","article-title":"Opioid-related side effects: postoperative ileus, urinary retention, nausea and vomiting, and shivering. A review of the literature","volume":"31","author":"de Boer HD","year":"2017","unstructured":"de Boer HD, Detriche O, Forget P. Opioid-related side effects: postoperative ileus, urinary retention, nausea and vomiting, and shivering. A review of the literature. Best Pract Res Clin Anaesthesiol. 2017, 31:499-504. 10.1016\/j.bpa.2017.07.002","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of Na(v)1.8 with VX-548 for acute pain","volume":"389","author":"Jones J","year":"2023","unstructured":"Jones J, Correll DJ, Lechner SM, et al.. Selective inhibition of Na(v)1.8 with VX-548 for acute pain. N Engl J Med. 2023, 389:393-405. 10.1056\/NEJMoa2209870","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-021-00444-w","article-title":"The physiological function of different voltage-gated sodium channels in pain","volume":"22","author":"Goodwin G","year":"2021","unstructured":"Goodwin G, McMahon SB. The physiological function of different voltage-gated sodium channels in pain. Nat Rev Neurosci. 2021, 22:263-74. 10.1038\/s41583-021-00444-w","journal-title":"Nat Rev Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02178-w","article-title":"Suzetrigine: first approval","volume":"85","author":"Keam SJ","year":"2025","unstructured":"Keam SJ. Suzetrigine: first approval. Drugs. 2025, 85:845-51. 10.1007\/s40265-025-02178-w","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2503570122","article-title":"Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor suzetrigine","volume":"122","author":"Stewart RG","year":"2025","unstructured":"Stewart RG, Osorno T, Fujita A, Jo S, Ferraiuolo A, Carlin K, Bean BP. Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor suzetrigine. Proc Natl Acad Sci. 2025, 122:e2503570122. 10.1073\/pnas.2503570122","journal-title":"Proc Natl Acad Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of Suzetrigine, a potent and selective Na(v)1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen JD","year":"2025","unstructured":"Osteen JD, Immani S, Tapley TL, et al.. Pharmacology and mechanism of action of Suzetrigine, a potent and selective Na(v)1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther. 2025, 14:655-74. 10.1007\/s40122-024-00697-0","journal-title":"Pain Ther"},{"key":"ref14","unstructured":"JOURNAVX (suzetrigine) prescribing information. (2025). Accessed. February 10, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219209s000lbl.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaf219","article-title":"Suzetrigine: a novel selective sodium channel inhibitor for pain","volume":"83","author":"Courtney D","year":"2026","unstructured":"Courtney D, Potru S, Mathew P. Suzetrigine: a novel selective sodium channel inhibitor for pain. Am J Health Syst Pharm. 2026, 83:245-53. 10.1093\/ajhp\/zxaf219","journal-title":"Am J Health Syst Pharm"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000005460","article-title":"Suzetrigine, a nonopioid Nav 1.8 inhibitor for treatment of moderate-to-severe acute pain: two Phase 3 randomized clinical trials","volume":"142","author":"Bertoch T","year":"2025","unstructured":"Bertoch T, D'Aunno D, McCoun J, et al.. Suzetrigine, a nonopioid Nav 1.8 inhibitor for treatment of moderate-to-severe acute pain: two Phase 3 randomized clinical trials. Anesthesiology. 2025, 142:1085-99. 10.1097\/ALN.0000000000005460","journal-title":"Anesthesiology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco AC","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al.. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018, 169:467-73. 10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey H","year":"2005","unstructured":"Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005, 8:19-32. 10.1080\/1364557032000119616","journal-title":"Int J Soc Res Methodol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000277","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"19","author":"Peters MD","year":"2021","unstructured":"Peters MD, Marnie C, Tricco AC, et al.. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Implement. 2021, 19:3-10. 10.1097\/XEB.0000000000000277","journal-title":"JBI Evid Implement"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S509144","article-title":"Suzetrigine, a non-opioid Na(v)1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a Phase 3 single-arm study for surgical or non-surgical acute pain","volume":"18","author":"McCoun J","year":"2025","unstructured":"McCoun J, Winkle P, Solanki D, et al.. Suzetrigine, a non-opioid Na(v)1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a Phase 3 single-arm study for surgical or non-surgical acute pain. J Pain Res. 2025, 18:1569-76. 10.2147\/JPR.S509144","journal-title":"J Pain Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1101\/2025.04.09.648014","article-title":"Suzetrigine (VX-548) exhibits activity-dependent effects on human dorsal root ganglion neurons","author":"Uhelski ML","year":"2025","unstructured":"Uhelski ML, Schaub MK, Espinosa F, et al.. Suzetrigine (VX-548) exhibits activity-dependent effects on human dorsal root ganglion neurons. bioRxiv. 2025, 10.1101\/2025.04.09.648014","journal-title":"bioRxiv"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210760","article-title":"Suzetrigine, a selective pain signal inhibitor of NaV1.8 shows proof-of-concept for treatment of painful diabetic peripheral neuropathy (S11.002)","volume":"104","author":"Freeman R","year":"2025","unstructured":"Freeman R, Rauck R, Argoff C, et al.. Suzetrigine, a selective pain signal inhibitor of NaV1.8 shows proof-of-concept for treatment of painful diabetic peripheral neuropathy (S11.002). Neurology. 2025, 104:3054. 10.1212\/WNL.0000000000210760","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2025-ESRA.201","article-title":"EP132\u2005Initial prescribing practices of suzetrigine for patients with chronic pain","volume":"50","author":"Sideris A","year":"2025","unstructured":"Sideris A, Richman D, Malhotra A, et al.. EP132\u2005Initial prescribing practices of suzetrigine for patients with chronic pain. Reg Anesth & Pain Med. 2025, 50:A127. 10.1136\/rapm-2025-ESRA.201","journal-title":"Reg Anesth & Pain Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.21.634079\u00a0","article-title":"Small molecule-mediated targeted protein degradation of voltage-gated sodium channels involved in pain","author":"\u00a0Chamessian\u00a0A","year":"2025","unstructured":"\u00a0Chamessian\u00a0A, Payne M, Gordon I, Zhou M, Gereau R. Small molecule-mediated targeted protein degradation of voltage-gated sodium channels involved in pain. bioRxiv. 2025, 10.1101\/2025.01.21.634079\u00a0","journal-title":"bioRxiv"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.124.000944","article-title":"State-dependent inhibition of NaV1.8 sodium channels by VX-150 and VX-548","volume":"106","author":"Vaelli P","year":"2024","unstructured":"Vaelli P, Fujita A, Jo S, Zhang HB, Osorno T, Ma X, Bean BP. State-dependent inhibition of NaV1.8 sodium channels by VX-150 and VX-548. Mol Pharmacol. 2024, 106:298-308. 10.1124\/molpharm.124.000944","journal-title":"Mol Pharmacol"},{"key":"ref26","unstructured":"Evaluation of efficacy and safety of VX-548 for painful diabetic peripheral neuropathy. (2026). Accessed. February 10, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05660538."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522742-suzetrigine-a-selective-inhibitor-of-the-nav18-sodium-channel","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:31:49Z","timestamp":1788024709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522742-suzetrigine-a-selective-inhibitor-of-the-nav18-sodium-channel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.115406","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}